MedTrace Logo

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

NCT05110209 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 331541

Last updated 2021-12-21

No results posted yet for this study

Summary

In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs. The study was conducted using the IRIS Registry, and all results were based on the study period from 01/01/2019 to 12/31/2019.

Conditions

  • Age-related Macular Degeneration (AMD)

Interventions

OTHER

Aflibercept

intravitreal injection

OTHER

Ranibizumab

intravitreal injection

OTHER

Bevacizumab

intravitreal injection

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2020-11-20
Completion
2020-11-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05110209 on ClinicalTrials.gov